



IFW

Docket No.: 0480-0165PUS1  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Richard BÉLIVEAU et al.

Application No.: 10/556,145

Confirmation No.: 5957

Filed: August 21, 2006

Art Unit: N/A

For: **COMPOUND AND METHOD FOR  
REGULATING PLASMINOGEN  
ACTIVATION AND CELL MIGRATION**

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT**  
**(SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL  
REJECTION OR NOTICE OF ALLOWANCE OR CONCURRENTLY WITH A RULE  
1.114 RCE APPLICATION)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

**I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION**

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-SB08(s), attached hereto.

**II. COPIES**

a. Copies of cited U.S. patents and patent application publications are not included.  
Copies of foreign patent documents and non-patent literature are included.

b. Some or all of the documents listed on the PTO-SB08 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

c. REFERENCES PREVIOUSLY CITED OR SUBMITTED - Pursuant to 37 C.F.R. §1.98(d), consideration of information listed on the PTO-SB08 form(s) is requested since any patents, publications, or other information which are listed on the PTO-SB08 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No(s) and U.S. Filing Date

PCT/CA2004/000697 filed May 7, 2004

III. CONCISE EXPLANATION OF THE RELEVANCE

(check at least one box)

a. DOCUMENTS IN THE ENGLISH LANGUAGE - The patents, publications, or other information listed on the attached PTO SB08 are in the English language and therefore, do not require a statement of relevancy.

b. DOCUMENTS NOT IN THE ENGLISH LANGUAGE - A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. ENGLISH LANGUAGE SEARCH REPORT - An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).

d. OTHER - The following additional information is provided for the Examiner's consideration.

IV. FEES (check one box)

a. This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

b. This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

c. This Information Disclosure Statement is being filed within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required. *(This section is not to be used with RCE's.)*

d. This Information Disclosure Statement is being filed within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required.

e. This Information Disclosure Statement is being filed concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.

f. This Information Disclosure Statement is being filed before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account for the fee as required by 37 C.F.R. § 1.17(p).

g. This Information Disclosure Statement is being filed before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).

No statement; therefore, a fee as required by 37 C.F.R. § 1.17(p) is attached.

or

See the statement below. No fee is required.

V. STATEMENT UNDER 37 C.F.R. § 1.97(e)

(check only one box)

The undersigned hereby states that:

a. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or

b. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

c. No item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.

d. Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VI. PAYMENT OF FEES (check one box)

The required fee is listed on the attached Fee Transmittal.

No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.


Dated: May 3, 2007

Respectfully submitted,

By  #42874.  
Mark J. Nuell  
Registration No.: 36,623  
BIRCH, STEWART, KOLASCH & BIRCH, LLP  
8110 Gatehouse Road  
Suite 100 East  
P.O. Box 747  
Falls Church, Virginia 22040-0747  
(703) 205-8000  
Attorney for Applicant

Attachment(s):

PTO/SB/08  
 Document(s)  
 Foreign Search Report(s)  
 Fee  
 Other:



Used in Lieu of PTO/SB/08A/B  
(Based on PTO 04-07 version)

|                              |   |    |   |                        |                        |
|------------------------------|---|----|---|------------------------|------------------------|
| Substitute for form 1449/PTO |   |    |   | Complete if Known      |                        |
|                              |   |    |   | Application Number     | 10/556,145-Conf. #5957 |
|                              |   |    |   | Filing Date            | August 21, 2006        |
|                              |   |    |   | First Named Inventor   | Richard BÉLIVEAU       |
|                              |   |    |   | Art Unit               | N/A                    |
|                              |   |    |   | Examiner Name          | Not Yet Assigned       |
| Sheet                        | 1 | of | 1 | Attorney Docket Number | 0480-0165PUS1          |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials               | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
| CA                              |                       | Alemany et al., 1993, J Cell Sci, 104:1155-1162.  |                |
| CB                              |                       | Andreasen et al., 1997, Int. J Cancer, 72:1-22.   |                |
| CC                              |                       | Baker et al., 1992, FEBS Letters, 298(2,3):215-218.   |                |
| CD                              |                       | Bass et al., 2002, J Biol Chem, 277(49):46845-46848.  |                |
| CE                              |                       | Brown et al., 1981, Proc Natl Acad Sci USA, 78(1):539-543.  |                |
| CF                              |                       | Brown et al., 1982, Nature, 296:171-173   |                |
| CG                              |                       | Bu et al., 1996, J Biol Chem, 271(36):22218-22224   |                |
| CH                              |                       | Conese et al., 1995, J Cell Biol, 131(6):1609-1622  |                |
| CI                              |                       | Cubellis et al., 1989, Proc Natl Acad Sci USA, 86:4828-4832   |                |
| CJ                              |                       | Dano et al., 1985, Adv Cancer Res, 44:139-266   |                |
| CK                              |                       | Dehouck et al., 1992, J Neurochem, 58 (5):1790-1797   |                |
| CL                              |                       | Demeule, et al., 2002 J Neurochem 83:924-933  |                |
| CM                              |                       | Fillebein et al., 1999 J Biol Chem 274(11):7011-7017  |                |
| CN                              |                       | Food et al., 1994 J Biol Chem. 269(4):3034-3040   |                |
| CO                              |                       | Gong et al., 2001 J Biol Chem 276(22):19078-19083   |                |
| CP                              |                       | Herz et al., 2001 J Clin Invest 108(6):779-784  |                |
| CQ                              |                       | Jefferies et al., 1996 Brain Res 712:122-126  |                |
| CR                              |                       | Johnsson et al., 1991 Anal Biochem 198:268-277  |                |
| CS                              |                       | Kennard et al., 1996 Nat Med 2:1230-1235  |                |
| CT                              |                       | Kozyraki et al., 2001 Proc Natl Acad Sci USA 98(22):12491-12496   |                |
| CU                              |                       | Li et al., 2002 J Biol Chem 277(44):42366-42371   |                |
| CV                              |                       | Liu et al., 2002 J. Biol Chem 276(31):28889-28896   |                |
| CW                              |                       | Min et al., 1996 Cancer Res 56:2428-2433  |                |
| CX                              |                       | Neels et al., 1999 J Biol Chem 274(44):31305-31311  |                |
| CY                              |                       | Nielsen et al., 1988 J. Biol Chem 263(5):2358-2363  |                |
| CZ                              |                       | Nykaer et al., 1997 EMBO J 16(10):2610-2620   |                |
| CA1                             |                       | Olson et al., 1992 J Biol Chem 267(13):9129-9133  |                |
| CB1                             |                       | Ploug et al., 1991 J Biol Chem 266(3):1926-1933   |                |
| CC1                             |                       | Reijerkerk et al., 2000 Eur J Cancer, 36:1695-1705  |                |
| CD1                             |                       | Richardson, 2000 Eur J. Biochem 267:1290-1298   |                |
| CE1                             |                       | Sekyere et al., 2000 FEBS Letters 483:11-16   |                |
| CF1                             |                       | Stahl et al., 1997 Int J Cancer 71:116-122  |                |
| CG1                             |                       | Tarui et al., 2002 J Biol Chem 277(37):33564-33570  |                |
| CH1                             |                       | Weaver et al., 1997 J Biol Chem 272(22):14372-14379   |                |
| CI1                             |                       | Woodbury et al., 1980 Proc Natl Acad Sci USA 77(4):2183-2187  |                |
| CJ1                             |                       | Woodbury et al., 1981, Int J Cancer, 27:145-149   |                |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|